ArticleTransboundary and emerging diseases2025
A Triplex Propidium Monoazide (PMA) qPCR Assay Enables Rapid Discrimination of Live Porcine Reproductive and Respiratory Syndrome Viruses.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Innovations, Applications, and Future Trends in Veterinary Diagnostic Technologies.Transboundary and emerging diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The devastating swine disease, porcine reproductive and respiratory syndrome (PRRS), can only be caused by live PRRS virus (PRRSV) infection. However, the most commonly used detection methods cannot discriminate PRRSV infectivity. Here we developed a triplex propidium monoazide (PMA) qPCR assay for differential detection of infectious PRRSV isolates (NADC34-like PRRSV-2, NADC30-like PRRSV-2, and HP-PRRSV-2) prevalent in China. First, the PRRSV inactivation strategy was selected by comparing distinct inactivation methods. Subsequently, we optimized PMA pretreatment parameters and concentrations of primers and probes. The triplex PMA-qPCR assay displayed favorable specificity, sensitivity, and reproducibility. Moreover, 452 clinical samples (environmental feces, lungs, lymph nodes (LNs), and sera) were submitted to differential detection by triplex qPCR and triplex PMA-qPCR assays. A total of 83 PRRSV-positive samples were detected by the triplex qPCR assay, including 25 NADC34-like, 48 NADC30-like, and 15HP-PRRSV-2-positive samples (two samples were coinfected by NADC34-like and NADC30-like PRRSV-2, while three samples were coinfected by NADC30-like and HP-PRRSV-2). Meanwhile, 65 samples were identified by the PMA-qPCR method, including 21 NADC34-like, 36 NADC30-like, and 9HP-PRRSV-2 positive samples (one sample was coinfected by NADC34-like and NADC30-like PRRSV-2). No PRRSV could be isolated from the 18 qPCR-positive but PMA-qPCR-negative samples. Overall, this study provides the first triplex PMA-qPCR assay for rapid discrimination of live PRRSV isolates in clinical samples, particularly in environmental feces.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.